Issue 5, 2009

Bioanalysis of recombinant proteins and antibodies by mass spectrometry

Abstract

In recent years, biotechnologically-derived drugs have been a major focus of research and development in the pharmaceutical industry. Their pharmacokinetics and pharmacokinetic/pharmacodynamic relationships impact every stage of the development process and require their assessment in the circulation in preclinical species and in humans. To this end, immunoassays are a reference, but standardisation remains an issue owing to the restricted pattern of antibody specificity and interference with endogenous components. As an alternative, we report here analytical strategies involving liquid chromatography coupled to mass spectrometry (LC-MS) for the accurate quantification of therapeutic proteins and antibodies in biological fluids.

Graphical abstract: Bioanalysis of recombinant proteins and antibodies by mass spectrometry

Article information

Article type
Minireview
First published
24 Mar 2009

Analyst, 2009,134, 825-834

Bioanalysis of recombinant proteins and antibodies by mass spectrometry

E. Ezan, M. Dubois and F. Becher, Analyst, 2009, 134, 825 DOI: 10.1039/B819706G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements